Bloomberg Cites PHE Alzheimer’s Disease Study
A new PHE study, commissioned by the Alzheimer’s Association, investigates the potential savings of obtaining an earlier diagnosis. As reported in Bloomberg, PHE’s study demonstrated that an increase in early diagnosis of Alzheimer’s would lead to significant savings for the US—potentially up to $7.9 trillion over the lifetimes of everyone alive right now.
To read the details in Bloomberg, please click here.
By: Jason Shafrin, PhD Sr. Director, Policy and Economics and Jacki Chou, MPL Senior Director, Policy and Economics The recent announcement that CVS Caremark will use value-based metrics to inform formulary design at first appears a step in the right direction. However, using value measurements from a single nongovernmental organization—the Institute for Clinical and Economic Review (ICER)—based on a limited picture of treatment value may be problematic. Using this single assessment of value in an effort solely to exclude drugs from a major insurance formulary is even more worrisome and fails to recognize the heterogeneity in patient clinical needs and preferences.